Surge in Protein Demand Strains U.S. Dairy Industry
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Source: CNBC
- Dairy Shortages: The USDA reports that U.S. whey protein inventories have fallen by approximately 50% in 2023, leading to shortages among suppliers for the latter half of the year, indicating a tight market supply-demand situation.
- Price Surge: Whey protein isolate prices have reached $14 per pound, reflecting a spike in demand driven by the rising popularity of GLP-1 weight loss drugs, suggesting that protein consumption will continue to rise in the short term.
- Infrastructure Bottlenecks: As whey is a byproduct of cheese production, existing facilities cannot expand quickly, and the approval for additional filtration infrastructure can take years, limiting the supply chain's capacity to grow.
- Market Investment Opportunities: Major dairy companies like Dairy Farmers of America and Saputo are expected to be the first to increase capacity, and while current high prices may moderate in the coming years, it will take time for the market to adjust.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1127.690
Low
950.00
Averages
1192
High
1500
Current: 1127.690
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reaps Benefits from Weight Loss Drug
- Weight Loss Drug Success: Eli Lilly's weight loss treatment is performing exceptionally well in the market, driving significant growth in the company's performance and expected to enhance its competitive edge in the pharmaceutical industry.
- Investment Recommendation Analysis: Despite Eli Lilly's strong performance in the weight loss drug sector, it was not included in the current best stock picks by The Motley Fool Stock Advisor analyst team, indicating a cautious market outlook on its future growth.
- Historical Investment Returns: Looking back, Netflix and Nvidia were featured on The Motley Fool's recommendation list, where a $1,000 investment at the time would now be worth $382,359 and $1,201,390 respectively, showcasing the platform's investment potential.
- Market Performance Comparison: As of June 26, 2026, The Motley Fool Stock Advisor's total average return stands at 883%, significantly outperforming the S&P 500's 205%, reflecting the effectiveness of its stock selection strategy.
See More
Surge in Protein Demand Strains U.S. Dairy Industry
- Dairy Shortages: The USDA reports that U.S. whey protein inventories have fallen by approximately 50% in 2023, leading to shortages among suppliers for the latter half of the year, indicating a tight market supply-demand situation.
- Price Surge: Whey protein isolate prices have reached $14 per pound, reflecting a spike in demand driven by the rising popularity of GLP-1 weight loss drugs, suggesting that protein consumption will continue to rise in the short term.
- Infrastructure Bottlenecks: As whey is a byproduct of cheese production, existing facilities cannot expand quickly, and the approval for additional filtration infrastructure can take years, limiting the supply chain's capacity to grow.
- Market Investment Opportunities: Major dairy companies like Dairy Farmers of America and Saputo are expected to be the first to increase capacity, and while current high prices may moderate in the coming years, it will take time for the market to adjust.
See More
Medicare's New Policy Expands Access to Obesity Drugs
- Medicare Coverage Breakthrough: Starting July 1, eligible seniors can access obesity drugs through Medicare's Bridge program for a monthly copay of $50, marking a significant victory for patients and advocates, which is expected to greatly enhance the accessibility of obesity treatments.
- Public Awareness Gap: A survey indicates that 82% of older Americans are unaware of Medicare's upcoming coverage for obesity drugs, which may delay many eligible patients from taking advantage of the new policy, potentially impacting treatment outcomes and health improvements.
- Marketing Strategy Concerns: Despite Novo Nordisk and Eli Lilly's substantial advertising expenditures on obesity drugs, their limited outreach to seniors may hinder awareness and uptake of the new coverage, especially during the initial rollout phase.
- Complex Eligibility Process: Unlike traditional Medicare drug coverage, the Bridge program requires patients to meet specific eligibility criteria and obtain prior authorization, which could create barriers for some patients in accessing timely treatment.
See More
Winners and Losers in the AI Boom Debate
- Micron's Earnings Ignite Market Reaction: Micron's earnings report revealed over a fourfold year-over-year revenue increase and provided guidance exceeding Wall Street expectations, despite a 13% drop on Tuesday, the stock rebounded 16% on Thursday, reflecting market confidence in its long-term supply agreements.
- Apple's Price Increases: Apple announced price hikes for several MacBook and iPad models due to soaring memory and storage costs, resulting in a 6.1% drop in stock price on Thursday, marking its first formal move to pass costs to consumers and highlighting hardware bottlenecks affecting tech giants.
- Semiconductor Sector Volatility: Concerns over the sustainability of AI infrastructure funding arose after reports that OpenAI might delay its IPO, leading to a more than 5% drop in semiconductor stocks on Friday, with Micron ultimately finishing the week down 0.15%.
- Falling Oil Prices Ease Inflation Concerns: While tech stocks struggled, falling oil prices to around $69 per barrel alleviated inflation worries, boosting economically sensitive stocks and helping the Dow Jones Industrial Average achieve a modest weekly gain.
See More
Investors Navigate Divergent Signals in Stock Market
- Divergent Market Signals: The current stock market exhibits clear divergence, with Eli Lilly showing strong performance, indicating ongoing growth potential in the pharmaceutical sector, while Tesla's EV sales outlook faces uncertainty, potentially impacting its market share and investor confidence.
- Eli Lilly's Strong Performance: Eli Lilly's stock has risen in recent trading, reflecting investor optimism regarding its new drug development and market expansion, which not only boosts the company's market capitalization but may also attract more institutional investors.
- Sales Pressure on Tesla: Tesla is facing challenges with slowing EV sales, raising concerns about its future growth and potentially leading to stock price volatility that could affect overall investor sentiment in the electric vehicle market.
- Investor Strategy Adjustment: In this market environment, investors need to reassess their portfolios, focusing on industry leaders like Eli Lilly while cautiously approaching companies like Tesla that are facing challenges to mitigate potential risks.
See More
Opportunity to Buy Quality Stocks at Low Prices
- Market Opportunity: Investors have the chance to buy quality stocks at low prices based on afternoon prices from June 24, 2026, which may create a solid foundation for future investment returns.
- Investor Sentiment: The video published on June 26, 2026, reflects an optimistic attitude among investors regarding the current market conditions, believing that low-priced stocks will yield potential appreciation opportunities.
- Price Volatility Analysis: The timing of purchasing low-priced stocks may be related to overall market trends, prompting investors to monitor market dynamics to seize the best entry points for capital appreciation.
- Long-term Investment Strategy: The strategy of buying quality stocks at low prices may offer investors the potential for long-term gains, especially during market recoveries, effectively enhancing the overall performance of their investment portfolios.
See More
Eli Lilly Reaps Benefits from Weight Loss Drug
- Weight Loss Drug Success: Eli Lilly's weight loss treatment is performing exceptionally well in the market, driving significant growth in the company's performance and expected to enhance its competitive edge in the pharmaceutical industry.
- Investment Recommendation Analysis: Despite Eli Lilly's strong performance in the weight loss drug sector, it was not included in the current best stock picks by The Motley Fool Stock Advisor analyst team, indicating a cautious market outlook on its future growth.
- Historical Investment Returns: Looking back, Netflix and Nvidia were featured on The Motley Fool's recommendation list, where a $1,000 investment at the time would now be worth $382,359 and $1,201,390 respectively, showcasing the platform's investment potential.
- Market Performance Comparison: As of June 26, 2026, The Motley Fool Stock Advisor's total average return stands at 883%, significantly outperforming the S&P 500's 205%, reflecting the effectiveness of its stock selection strategy.
See More
Surge in Protein Demand Strains U.S. Dairy Industry
- Dairy Shortages: The USDA reports that U.S. whey protein inventories have fallen by approximately 50% in 2023, leading to shortages among suppliers for the latter half of the year, indicating a tight market supply-demand situation.
- Price Surge: Whey protein isolate prices have reached $14 per pound, reflecting a spike in demand driven by the rising popularity of GLP-1 weight loss drugs, suggesting that protein consumption will continue to rise in the short term.
- Infrastructure Bottlenecks: As whey is a byproduct of cheese production, existing facilities cannot expand quickly, and the approval for additional filtration infrastructure can take years, limiting the supply chain's capacity to grow.
- Market Investment Opportunities: Major dairy companies like Dairy Farmers of America and Saputo are expected to be the first to increase capacity, and while current high prices may moderate in the coming years, it will take time for the market to adjust.
See More
Medicare's New Policy Expands Access to Obesity Drugs
- Medicare Coverage Breakthrough: Starting July 1, eligible seniors can access obesity drugs through Medicare's Bridge program for a monthly copay of $50, marking a significant victory for patients and advocates, which is expected to greatly enhance the accessibility of obesity treatments.
- Public Awareness Gap: A survey indicates that 82% of older Americans are unaware of Medicare's upcoming coverage for obesity drugs, which may delay many eligible patients from taking advantage of the new policy, potentially impacting treatment outcomes and health improvements.
- Marketing Strategy Concerns: Despite Novo Nordisk and Eli Lilly's substantial advertising expenditures on obesity drugs, their limited outreach to seniors may hinder awareness and uptake of the new coverage, especially during the initial rollout phase.
- Complex Eligibility Process: Unlike traditional Medicare drug coverage, the Bridge program requires patients to meet specific eligibility criteria and obtain prior authorization, which could create barriers for some patients in accessing timely treatment.
See More
Winners and Losers in the AI Boom Debate
- Micron's Earnings Ignite Market Reaction: Micron's earnings report revealed over a fourfold year-over-year revenue increase and provided guidance exceeding Wall Street expectations, despite a 13% drop on Tuesday, the stock rebounded 16% on Thursday, reflecting market confidence in its long-term supply agreements.
- Apple's Price Increases: Apple announced price hikes for several MacBook and iPad models due to soaring memory and storage costs, resulting in a 6.1% drop in stock price on Thursday, marking its first formal move to pass costs to consumers and highlighting hardware bottlenecks affecting tech giants.
- Semiconductor Sector Volatility: Concerns over the sustainability of AI infrastructure funding arose after reports that OpenAI might delay its IPO, leading to a more than 5% drop in semiconductor stocks on Friday, with Micron ultimately finishing the week down 0.15%.
- Falling Oil Prices Ease Inflation Concerns: While tech stocks struggled, falling oil prices to around $69 per barrel alleviated inflation worries, boosting economically sensitive stocks and helping the Dow Jones Industrial Average achieve a modest weekly gain.
See More
Investors Navigate Divergent Signals in Stock Market
- Divergent Market Signals: The current stock market exhibits clear divergence, with Eli Lilly showing strong performance, indicating ongoing growth potential in the pharmaceutical sector, while Tesla's EV sales outlook faces uncertainty, potentially impacting its market share and investor confidence.
- Eli Lilly's Strong Performance: Eli Lilly's stock has risen in recent trading, reflecting investor optimism regarding its new drug development and market expansion, which not only boosts the company's market capitalization but may also attract more institutional investors.
- Sales Pressure on Tesla: Tesla is facing challenges with slowing EV sales, raising concerns about its future growth and potentially leading to stock price volatility that could affect overall investor sentiment in the electric vehicle market.
- Investor Strategy Adjustment: In this market environment, investors need to reassess their portfolios, focusing on industry leaders like Eli Lilly while cautiously approaching companies like Tesla that are facing challenges to mitigate potential risks.
See More
Opportunity to Buy Quality Stocks at Low Prices
- Market Opportunity: Investors have the chance to buy quality stocks at low prices based on afternoon prices from June 24, 2026, which may create a solid foundation for future investment returns.
- Investor Sentiment: The video published on June 26, 2026, reflects an optimistic attitude among investors regarding the current market conditions, believing that low-priced stocks will yield potential appreciation opportunities.
- Price Volatility Analysis: The timing of purchasing low-priced stocks may be related to overall market trends, prompting investors to monitor market dynamics to seize the best entry points for capital appreciation.
- Long-term Investment Strategy: The strategy of buying quality stocks at low prices may offer investors the potential for long-term gains, especially during market recoveries, effectively enhancing the overall performance of their investment portfolios.
See More
